Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -9.01%1.64B | ---- | 24.02%1.8B | ---- | -45.17%1.45B | ---- | 98.41%2.65B | ---- | -30.33%1.34B |
| Profit adjustment | ||||||||||
| Impairment and provisions: | ---- | ---- | ---- | --100.17M | ---- | ---- | ---- | --225.49M | ---- | ---- |
| -Other impairments and provisions | ---- | ---- | ---- | --100.17M | ---- | ---- | ---- | --225.49M | ---- | ---- |
| Revaluation surplus: | ---- | 386.39%4.29M | ---- | -36.23%882K | ---- | 198.50%1.38M | ---- | -207.01%-1.4M | ---- | 255.82%1.31M |
| -Fair value of investment properties (increase) | ---- | 386.39%4.29M | ---- | -36.23%882K | ---- | 198.50%1.38M | ---- | -207.01%-1.4M | ---- | 255.82%1.31M |
| Asset sale loss (gain): | ---- | -20,675.39%-65.86M | ---- | 51.45%-317K | ---- | 99.93%-653K | ---- | -133,339.58%-960.77M | ---- | 98.10%-720K |
| -Loss (gain) from sale of subsidiary company | ---- | ---65.84M | ---- | ---- | ---- | ---- | ---- | ---960.98M | ---- | ---- |
| -Loss (gain) on sale of property, machinery and equipment | ---- | 94.32%-18K | ---- | 51.45%-317K | ---- | -409.48%-653K | ---- | 129.31%211K | ---- | -548.65%-720K |
| Depreciation and amortization: | ---- | 18.19%1.55B | ---- | 11.29%1.31B | ---- | 8.03%1.18B | ---- | 11.46%1.09B | ---- | 52.38%976.16M |
| -Amortization of intangible assets | ---- | 18.41%1.52B | ---- | 11.47%1.28B | ---- | 8.37%1.15B | ---- | 11.92%1.06B | ---- | 48.29%949.92M |
| Special items | ---- | -20.46%-89.14M | ---- | -56.29%-74M | ---- | -114.04%-47.35M | ---- | -20.53%-22.12M | ---- | -181.53%-18.35M |
| Operating profit before the change of operating capital | ---- | -3.25%3.04B | ---- | 21.50%3.14B | ---- | -13.38%2.58B | ---- | 29.93%2.98B | ---- | -9.76%2.3B |
| Change of operating capital | ||||||||||
| Accounts receivable (increase)decrease | ---- | -666.11%-35.85M | ---- | -81.52%6.33M | ---- | 266.15%34.27M | ---- | -7,956.64%-20.63M | ---- | -101.90%-256K |
| Accounts payable increase (decrease) | ---- | -170.06%-90.05M | ---- | 52.60%-33.34M | ---- | -169.83%-70.34M | ---- | 300.48%100.73M | ---- | 119.60%25.15M |
| Special items for working capital changes | ---- | 39.99%84.3M | ---- | 102.88%60.22M | ---- | 386.27%29.68M | ---- | --6.1M | ---- | ---- |
| Cash from business operations | 21.80%1.65B | -5.58%3B | -9.16%1.36B | 23.09%3.17B | 19.01%1.49B | -16.03%2.58B | -13.96%1.25B | 32.25%3.07B | 179.22%1.46B | -4.47%2.32B |
| China income tax paid | -18.37%-203.35M | 10.06%-336.99M | -13.27%-171.79M | -2.17%-374.68M | 16.22%-151.66M | 26.53%-366.72M | 7.96%-181.02M | -129.42%-499.16M | -125.74%-196.68M | 24.24%-217.58M |
| Net cash from operations | 22.29%1.45B | -4.98%2.66B | -11.70%1.18B | 26.56%2.8B | 24.95%1.34B | -13.98%2.21B | -14.89%1.07B | 22.19%2.57B | 189.94%1.26B | -1.82%2.1B |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | -18.32%14.22M | -1.20%30.01M | 24.11%17.41M | -52.95%30.37M | -51.36%14.03M | 69.11%64.55M | 68.63%28.84M | 61.54%38.17M | 38.72%17.1M | -16.12%23.63M |
| Dividend received - investment | -54.48%45.02M | -40.47%212.82M | -43.03%98.91M | -24.02%357.52M | -44.87%173.6M | 133.30%470.53M | 478.04%314.88M | 326.64%201.69M | 730.25%54.47M | -88.20%47.27M |
| Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---6.41M | ---- | ---- | ---- | ---- |
| Sale of fixed assets | 112.50%34K | -26.63%248K | -89.87%16K | -37.52%338K | -68.90%158K | 270.55%541K | 225.64%508K | -87.32%146K | --156K | 1,238.37%1.15M |
| Purchase of fixed assets | 38.94%-7.55M | -0.26%-27.7M | -58.65%-12.36M | -12.97%-27.63M | -2.02%-7.79M | -10.84%-24.45M | 3.73%-7.64M | -49.92%-22.06M | 30.31%-7.93M | -211.21%-14.72M |
| Sale of subsidiaries | ---- | --93.98M | ---- | ---- | ---- | ---- | ---- | --2.03B | ---- | ---- |
| Acquisition of subsidiaries | ---- | ---614.38M | ---- | ---- | ---- | ---861.66M | ---- | ---- | ---- | ---- |
| Cash on investment | 42.82%-92.47M | 94.49%-50.57M | 70.48%-161.72M | ---916.93M | ---547.76M | ---- | ---- | -741.23%-639M | ---- | ---75.96M |
| Other items in the investment business | -111.16%-344.43M | -56.00%-945.51M | -83.37%-163.11M | -94.59%-606.1M | 17.16%-88.96M | 4.04%-311.47M | -9.71%-107.38M | -47.60%-324.58M | -148.46%-97.88M | -130.70%-219.9M |
| Net cash from investment operations | -74.40%-385.18M | -11.93%-1.3B | 51.64%-220.86M | -73.92%-1.16B | -299.26%-456.72M | -152.00%-668.38M | 772.58%229.21M | 638.90%1.29B | 68.40%-34.08M | 95.67%-238.53M |
| Net cash before financing | 10.34%1.06B | -17.00%1.36B | 8.95%962.84M | 6.04%1.64B | -32.12%883.77M | -60.00%1.54B | 6.16%1.3B | 106.76%3.86B | 275.16%1.23B | 155.32%1.86B |
| Cash flow from financing activities | ||||||||||
| New borrowing | -71.23%333.7M | -30.25%2.03B | -24.87%1.16B | -41.21%2.92B | -35.40%1.54B | 18.92%4.96B | 103.92%2.39B | 440.99%4.17B | 149.36%1.17B | -86.00%771M |
| Refund | -11.28%-691.04M | 54.45%-1.24B | 63.75%-620.99M | 60.30%-2.73B | 59.13%-1.71B | 4.62%-6.87B | -10.21%-4.19B | -148.88%-7.2B | -191.86%-3.8B | -6.75%-2.89B |
| Issuance of bonds | -27.91%1.79B | 4.55%4.28B | 91.48%2.49B | 64.11%4.09B | -13.19%1.3B | -28.54%2.49B | -57.15%1.5B | 133.71%3.49B | 250.45%3.49B | 49.92%1.49B |
| Interest paid - financing | 21.05%-252.05M | 7.26%-538.16M | 14.07%-319.25M | -2.22%-580.29M | -5.49%-371.54M | 10.34%-567.67M | -8.19%-352.21M | 15.96%-633.16M | 12.76%-325.55M | -149.46%-753.41M |
| Dividends paid - financing | 9.10%-443.75M | -21.50%-810.68M | -85.88%-488.18M | 36.35%-667.21M | 61.47%-262.63M | -7.92%-1.05B | -52.17%-681.68M | -151.28%-971.36M | -15.88%-447.96M | 60.10%-386.57M |
| Absorb investment income | --192M | ---- | ---- | 140.00%160M | ---- | --66.67M | ---- | ---- | ---- | ---- |
| Issuance expenses and redemption of securities expenses | 39.39%-1.8B | -11.25%-5.47B | -42.31%-2.97B | -391.70%-4.92B | ---2.09B | 22.66%-1B | ---- | ---1.29B | ---903M | ---- |
| Other items of the financing business | ---- | 77.99%-125K | 95.62%-25K | 85.32%-568K | 85.24%-571K | -1,190.00%-3.87M | -474.89%-3.87M | 84.76%-300K | 83.15%-673K | 55.48%-1.97M |
| Net cash from financing operations | -15.10%-871.97M | -1.44%-1.76B | 52.61%-757.59M | 12.43%-1.73B | -18.42%-1.6B | 19.17%-1.98B | -63.97%-1.35B | -37.47%-2.45B | -35.59%-823.25M | -173.86%-1.78B |
| Effect of rate | -253.64%-169K | -13.73%44K | -91.16%110K | -88.79%51K | 124.54%1.24M | 123.14%455K | 43.70%-5.07M | -125.46%-1.97M | -571.61%-9M | 18.20%-872K |
| Net Cash | -7.21%190.44M | -304.29%-402.4M | 128.71%205.25M | 77.32%-99.53M | -1,392.65%-714.8M | -131.24%-438.76M | -111.88%-47.89M | 1,616.74%1.4B | 243.89%403.25M | 108.55%81.81M |
| Begining period cash | -16.90%1.98B | -4.01%2.38B | -4.01%2.38B | -15.02%2.48B | -15.02%2.48B | 92.52%2.92B | 92.52%2.92B | 5.64%1.52B | 5.64%1.52B | -40.04%1.44B |
| Cash at the end | -16.14%2.17B | -16.90%1.98B | 46.38%2.59B | -4.01%2.38B | -38.35%1.77B | -15.02%2.48B | 50.01%2.87B | 92.52%2.92B | 65.14%1.91B | 5.64%1.52B |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.